With a clinical management grant through the ALS Canada Research Program, Dr. Mark Ware is leading a team of Canadian researchers who will participate in the upcoming Phase 2 clinical trial designed to test the safety and efficacy of using cannabis (marijuana) extracts to better manage the symptoms of ALS. Previous studies have shown that cannabis-based medicines may improve quality of life by reducing pain, drooling, speech difficulties, breathing issues, depression and sleep disorders.

Dr. Ware explains how cannabis can influence such a variety of different symptoms and presents preliminary work that highlights the positive effects cannabis-based medications can have in ALS animal models.

Did you find this resource helpful?
YesNo
This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.